Encephalitis Induced by Immune Checkpoint Inhibitors
JAMA Neurol 78:864-873, Velasco, R.,et al, 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Clinicopathologic Conference, Acute human immunodeficiency virus type 1
NEJM 385:641-648, Case 24-2021, 2021
Clinicopathologic Conference, Systemic Juvenile Idiopathic Arthritis
NEJM 385:1220-1229, Case 29-2021, 2021
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Stroke Prevention by Anticoagulants in Daily Practice Depending on Atrial Fibrillation Pattern and Clinical Risk Factors
Stroke 52:3121-3131, Grimaldi-Bensouda, L.,et al, 2021
Clinical Outcomes in Atrial Fibrillation Patients with a History of Cancer Treated with Non-Vitamin K Antagonist Oral Anticoagulants
Stroke 52:3132-3141, Chan, Y.H.,et al, 2021
Clinicopathologic Conference, Seizure from Neurocysticercosis
NEJM 385:1894-1902, Case 34-2021, 2021
A 55-Year-Odd Man with Old Behavior and Abnormal Movements
Neurol 97:1090-1093, McIntosh, P. & Scott, B., 2021
Left Ventricular Dysfunction Among Patients with Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin
JAMA Neurol 78:1454-1460, Merkler, A.E.,et al, 2021
Sensory Ganglionopathy
NEJM 383:1657-1662, Amato, A.A. & Ropper, A.H., 2020
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Clinicopathologic conference, Vitamin D deficiency
NEJM 383:2462-2470, Case 39-2020, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Stroke Reperfusion Therapy Following Dabigatran Reversal with Idarucizumab in a National Cohort
Neurol 94:e1968-e1972, Barber, P.A.,et al, 2020
Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events with Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients with Atrial Fibrillation with a History of Intracranial Hemorrhage
JAMA Network Open 3:e206424, Tsai, C.T.,et al, 2020
Relapse of Severe Neurosarcoidosis with Switch from Originator Infliximab to Biosimilar
Neurol 94:991-993, Kidd, D.P.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Association of Innovations in Radiotherapy and Systemic Treatments with Clinical Outcomes in Patients with Melanoma Brain Metastasis From 2007 to 2016
JAMA doi:10.1001/JAMANETWORKOPEN.2020.8204, Brastianos, H.C.,et al, 2020
Distal Symmetric Polyneuropathy in 2020
JAMA 324:90-92, Callaghan, B.C.,et al, 2020
Second Drug Okayed for Rare Central Nervous System Disease
JAMA 324:224, Jaklevic, M.C., 2020
Burning Pain in the Legs
NEJM 383:e18, Sacks, C.A., 2020
One-Year Sustained Efficacy of Erenumab in Episodic Migraine
Neurol 95:e469-e479, Goadsby, P.J.,et al, 2020
Polymyalgia Rheumatica and Giant Cell Arteritis
JAMA 324:993-994, Buttgereit, F.,et al, 2020
Muscle Stiffness, Gait Instability, and Liver Cirrhosis in Wilsons Disease
Lancet 396:990, Kronlage, C.,et al, 2020
A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
NEJM 382:9-19,81, Amarenco, P.,et al, 2020
Acute Ischemic Stroke in Adolescents
Neurol 94:e158-e169, Rambaud, R.,et al, 2020
Duchenne Muscular Dystrophy
BMJ 368:L7012, Fox, H.,et al, 2020
Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants
Stroke 51:533-541, Shahjouei, S.,et al, 2020
A 70-year-old Man with Rapid Stepwise Paraparesis and Sensory Loss
Neurol 94:e651-e655, Krause, M.A.,et al, 2020
Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020
MT in Anticoagulated Patients
Neurol 94: e842-e850, LAllinec, V.,et al, 2020
Dabigatran Reversal Before Intravenous Tenecteplase in Acute Ischemic Stroke
Stroke 51:1616-1619, Beharry, J.,et al, 2020
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
NEJM 382:1599-1607,1650, Agnelli, G.,et al, 2020
Fat Embolism Syndrome in Sickle Cell Disease
J Clin Med 9:1-12, Tsitsikas, D.A.,et al, 2020
Convexity Subarachnoid Hemorrhage Soon after Starting a Direct Oral Anticoagulant in 2 Patients with Acute Infarction
J Stroke Cerebrovasc Dis 29:105216, Jugita, Y.,et al, 2020
Two Cases of Meningitis Associated with Ocrelizumab Therapy
Mult Scler Rel Dis 38:101866, Theriault, M. & Solomon, A.J., 2020
"CHOICES": An Acronym to Aid in Delineating Potential Causes of Non-Metabolic, Non-Infectious Acute Toxic Leukoencephalopathy
EJR OPEN 6:243-257, Koksel, Y.,et al, 2019
A Middle Aged Man with Back Pain and Heavy Legs
BMJ 366:e2420, Chanchlani, N. & Reading, N.G., 2019
Complete Response of Spinal Metastases from Non-Small Cell Lung Cancer with ALK Inhibitors
Neurol 93:217-219, Pellerino, A.,et al, 2019
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder
NEJM 381:614-625, Pittock, S.J.,et al, 2019
Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial
Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019
Long-Term Safety and Efficacy of Eculizumab in Generalized Myasthenia Gravis
Muscle Nerve 60:14-24, Muppidi, S.,et al, 2019
Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder (N-MOmentum): A Double-Blind, Randomised Placebo-Controlled Phase 2/3 Trial
Lancet 394:1352-1363,1304, Cree, B.A.C.,et al, 2019
Clinical Effectiveness of Direct Oral Anticoagulations vs Warfarin in Older Patients with Atrial Fibrillation and Ischemic Stroke
JAMA Neurol 76:1192-1202, Xian, Y.,et al, 2019
Diagnosis and Management of Dementia
JAMA 322:1589-1599, Arvanitakis, Z.,et al, 2019
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Cholesterol Lowering and Prevention of Stroke
Stroke 50:537-541, Hackam, D.G. & Hegele, R.A., 2019
Contemporary Reversal of Oral Anticoagulation in Intracerebral Hemorrhage
Stroke 50:529-536, Bower, M.M.,et al, 2019
Simultaneous CMV and Listeria Infection Following Alemtuzumab Treatment for Multiple Sclerosis
Neurol 92:296-298, Pappolla, A.,et al, 2019